Aclaris therapeutics to host in-person and webcast r&d day, “patient focused innovation: addressing gaps in immuno-inflammatory markets”, in new york on october 14, 2025

Wayne, pa., sept. 30, 2025 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the company will host it's 2025 r&d day in midtown, new york on tuesday, october 14, 2025 at 8:00 am et to discuss the company's progress in addressing therapeutic gaps in immuno-inflammatory markets.
ACRS Ratings Summary
ACRS Quant Ranking